Studies have demonstrated that elevated levels of METTL3 expression are correlated with advanced pathological stages in PDAC (Xia et al. 2019), as well as resistance to chemotherapy and radiotherapy in pancreatic cancer cells (Taketo et al. 2018). Here, METTL3 is linked to familial pancreatic carcinoma.